Literature DB >> 19046187

Neurological aspects of hyperinsulinism-hyperammonaemia syndrome.

Nadia Bahi-Buisson1, Emmanuel Roze, Carlo Dionisi, Fabienne Escande, Vassili Valayannopoulos, François Feillet, Claudine Heinrichs, Bernadette Chadefaux-Vekemans, Bernard Dan, Pascale de Lonlay.   

Abstract

Hyperinsulinism-hyperammonaemia syndrome (HHS) is a rare cause of congenital hyperinsulinism, due to missense mutations in the GLUD1 gene, resulting in glutamate dehydrogenase (GDH) overactivity. The aim of this study was to document the spectrum of neurological disturbances associated with HHS and to identify possible phenotype-genotype correlations. We retrospectively analyzed the neurological outcomes of 22 consecutive patients (12 males, 10 females) aged from 18 months to 40 years and diagnosed with HHS. We analyzed demographic and clinical features and neuroradiological, biochemical, and genetic findings. Fourteen patients had childhood-onset epilepsy. Learning disability was found in 17 patients. Two patients had pyramidal involvement and one had generalized dystonia. Seizures were observed in 11 of 19 patients with documented GLUD1 mutations, and nine of these 11 patients had a mutation in the guanosine triphosphate (GTP) binding site. Our data demonstrate that neurological disorders in HHS are more frequent than previously thought and might suggest that mutations in the GTP binding site of GDH could be associated with more frequent epilepsy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19046187     DOI: 10.1111/j.1469-8749.2008.03114.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  34 in total

Review 1.  The structure and allosteric regulation of mammalian glutamate dehydrogenase.

Authors:  Ming Li; Changhong Li; Aron Allen; Charles A Stanley; Thomas J Smith
Journal:  Arch Biochem Biophys       Date:  2011-11-04       Impact factor: 4.013

Review 2.  The structure and allosteric regulation of glutamate dehydrogenase.

Authors:  Ming Li; Changhong Li; Aron Allen; Charles A Stanley; Thomas J Smith
Journal:  Neurochem Int       Date:  2010-11-09       Impact factor: 3.921

Review 3.  Glutamate dehydrogenase: structure, allosteric regulation, and role in insulin homeostasis.

Authors:  Ming Li; Changhong Li; Aron Allen; Charles A Stanley; Thomas J Smith
Journal:  Neurochem Res       Date:  2013-10-12       Impact factor: 3.996

4.  Green tea polyphenols control dysregulated glutamate dehydrogenase in transgenic mice by hijacking the ADP activation site.

Authors:  Changhong Li; Ming Li; Pan Chen; Srinivas Narayan; Franz M Matschinsky; Michael J Bennett; Charles A Stanley; Thomas J Smith
Journal:  J Biol Chem       Date:  2011-08-03       Impact factor: 5.157

5.  Green Tea Polyphenols in drug discovery - a success or failure?

Authors:  Thomas J Smith
Journal:  Expert Opin Drug Discov       Date:  2011-06       Impact factor: 6.098

Review 6.  Congenital hyperinsulinism disorders: Genetic and clinical characteristics.

Authors:  Elizabeth Rosenfeld; Arupa Ganguly; Diva D De Leon
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-08-14       Impact factor: 3.908

7.  Neonatal hypoglycemia.

Authors:  Ved Bhushan Arya; Senthil Senniappan; Maria Guemes; Khalid Hussain
Journal:  Indian J Pediatr       Date:  2013-08-01       Impact factor: 1.967

Review 8.  Regulation of glutamate metabolism and insulin secretion by glutamate dehydrogenase in hypoglycemic children.

Authors:  Charles A Stanley
Journal:  Am J Clin Nutr       Date:  2009-07-22       Impact factor: 7.045

9.  Glutamate dehydrogenase 1 and SIRT4 regulate glial development.

Authors:  Daniel Komlos; Kara D Mann; Yue Zhuo; Christopher L Ricupero; Ronald P Hart; Alice Y-C Liu; Bonnie L Firestein
Journal:  Glia       Date:  2012-12-22       Impact factor: 7.452

Review 10.  Mechanisms of amino acid-stimulated insulin secretion in congenital hyperinsulinism.

Authors:  Tingting Zhang; Changhong Li
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2012-12-04       Impact factor: 3.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.